APS6-45
Selleck Chemicals
SKU:S3493-5MG
Couldn't load pickup availability

APS6-45 is an inhibitor linked to MAPK / ERK Signaling and related pathway-oriented research. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling in biochemical and cell-based models.
The pathway annotation connects APS6-45 to MAPK / ERK Signaling, supporting experiments that monitor mitogenic kinase cascades, proliferation control, and differentiation-linked signaling across biochemical, cellular, or phenotypic assay formats. This context is compatible with phosphorylation mapping, pathway-response, and growth assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. When a fully resolved mechanism is unavailable, parallel readouts such as viability, reporter activity, morphology, localization, or biochemical conversion can still help position the compound experimentally.
Research Applications
- Pathway perturbation studies connected to MAPK / ERK Signaling
- Concentration-response inhibition and target-dependence studies
- Combination studies with orthogonal perturbagens
- Mechanism-oriented follow-up using biochemical and cellular endpoints
Overall, APS6-45 is well suited to pathway-oriented studies that need a defined compound input for MAPK / ERK Signaling readouts in biochemical and cell-based models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Pathways:
- MAPK / ERK Signaling
- CAS No.:
- 2188236-41-9
- Molecular Weight:
- 548.39
- Formula:
- C₂₃H₁₆F₈N₄O₃
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.